A research-based guide to the peptides most studied for muscle growth, GH axis optimization, and training recovery — covering mechanisms, dosing protocols, stacking strategies, and cycle recommendations.
WADA Prohibited — All Compounds Listed
All peptides covered in this guide are prohibited by the World Anti-Doping Agency (WADA) under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Competitive athletes subject to anti-doping testing should not use these compounds. This guide is for research and educational purposes only.
IGF-1 LR3 directly activates the PI3K/Akt/mTOR signaling cascade — the master regulator of muscle protein synthesis. This is the same pathway activated by resistance training, but IGF-1 LR3 extends the anabolic window beyond the post-workout period.
CJC-1295 + Ipamorelin synergistically amplifies the natural GH pulse that occurs during deep sleep. CJC-1295 extends pulse amplitude; Ipamorelin triggers pulse frequency. Together they produce 3–5x baseline GH elevation without disrupting the pulsatile pattern.
IGF-1 LR3 activates muscle satellite cells (myogenic stem cells), promoting hyperplasia — the formation of new muscle fibers — rather than just hypertrophy of existing fibers. This mechanism is distinct from androgen receptor-mediated anabolism.
BPC-157 upregulates VEGF and activates the FAK-paxillin pathway, accelerating tendon and ligament repair. TB-500 regulates actin polymerization and reduces systemic inflammation. Together they protect connective tissue during high-volume training phases.
| Compound | Role | Mechanism | Research Dose | Cycle | Evidence |
|---|---|---|---|---|---|
| IGF-1 LR3Anabolic | Long R3 IGF-1 analogue. Activates mTOR and satellite cells post-workout. Most potent anabolic peptide in research. | IGF-1R → PI3K/Akt/mTOR → protein synthesis + satellite cell activation | 20–100mcg post-workout | 4–6 weeks, then equal off | Preclinical + Phase 1 |
| CJC-1295GH Axis | GHRH analogue. Amplifies GH pulse amplitude. With DAC: 8-day half-life, once-weekly dosing. | GHRH-R agonist → ↑ GH pulse amplitude → ↑ IGF-1 | 2mg/week (with DAC) or 100mcg 2–3x/day (no DAC) | 12 weeks on / 4 weeks off | Phase 1–2 |
| IpamorelinGH Secretagogue | Selective GHSR agonist. Triggers GH release without cortisol/prolactin elevation. Stacks synergistically with CJC-1295. | GHSR-1a agonist → selective GH pulse → ↑ IGF-1 | 200–300mcg 2–3x/day | Continuous or cycled | Phase 1–2 |
| BPC-157Recovery | Pentadecapeptide. Accelerates tendon, ligament, and muscle repair. Protects connective tissue during heavy training. | VEGF upregulation + FAK-paxillin pathway → angiogenesis + tissue repair | 250–500mcg/day near injury | 4–8 weeks | Preclinical (extensive) |
| TB-500Recovery | Thymosin Beta-4 fragment. Systemic anti-inflammatory, DOMS reduction. Stacks with BPC-157 as Wolverine Blend. | Actin regulation + MMP-2 upregulation → cell migration + anti-inflammation | 2–2.5mg 2x/week loading | 4–8 weeks | Preclinical + Phase 1 |
| GHK-CuSkin & Collagen | Copper-binding tripeptide. Stimulates collagen synthesis and skin elasticity — increasingly used during bulk/cut cycles. | TGF-β activation + MMP modulation → collagen synthesis + skin remodeling | 2–5mg/day injectable or topical | Continuous | Preclinical + Phase 1 |
Maximize muscle protein synthesis and GH/IGF-1 axis optimization
| Compound | Dose | Route | Timing |
|---|---|---|---|
| CJC-1295 (with DAC) | 2mg/week | SubQ | Any time |
| Ipamorelin | 200–300mcg | SubQ | 30–60 min pre-sleep |
| IGF-1 LR3 | 50–100mcg | SubQ | Post-workout |
Cycle: CJC/Ipa: 12 weeks on / 4 off · IGF-1 LR3: 4–6 weeks, then equal off
Note: IGF-1 LR3 should always be injected post-workout with carbohydrates available to prevent hypoglycemia.
Maintain training continuity and accelerate connective tissue repair
| Compound | Dose | Route | Timing |
|---|---|---|---|
| BPC-157 | 500mcg/day | SubQ near injury | AM or PM |
| TB-500 | 2mg 2x/week | SubQ abdomen | Any time |
Cycle: 4–8 weeks acute, then off cycle
Note: For active injuries, inject BPC-157 as close to the injury site as safely possible. TB-500 can be injected anywhere subcutaneously.
Body recomposition, fat loss, and skin quality during cut phase
| Compound | Dose | Route | Timing |
|---|---|---|---|
| CJC-1295 + Ipamorelin | 100mcg each 2–3x/day | SubQ | Fasted AM + pre-sleep |
| GHK-Cu | 2–3mg/day | SubQ or topical | PM |
Cycle: 12 weeks continuous
Note: GHK-Cu supports collagen synthesis and skin elasticity during caloric restriction when skin quality typically degrades.
mTOR activation, satellite cell proliferation, post-workout nutrient partitioning
GHRH analogue, GH pulse amplification, body recomposition over 12-week cycles
Selective GH release, no cortisol elevation, synergistic with CJC-1295
Long R3 IGF-1 analogue. Activates mTOR and satellite cells post-workout. Most potent anabolic peptide in research.
GHRH analogue. Amplifies GH pulse amplitude. With DAC: 8-day half-life, once-weekly dosing.
Selective GHSR agonist. Triggers GH release without cortisol/prolactin elevation. Stacks synergistically with CJC-1295.
Pentadecapeptide. Accelerates tendon, ligament, and muscle repair. Protects connective tissue during heavy training.
Thymosin Beta-4 fragment. Systemic anti-inflammatory, DOMS reduction. Stacks with BPC-157 as Wolverine Blend.
Copper-binding tripeptide. Stimulates collagen synthesis and skin elasticity — increasingly used during bulk/cut cycles.
| Goal | Primary Compound | Supporting Compound | Cycle Length |
|---|---|---|---|
| Maximum muscle growth | IGF-1 LR3 | CJC-1295 + Ipamorelin | 4–6 weeks (IGF-1 LR3) |
| Body recomposition | CJC-1295 + Ipamorelin | BPC-157 (maintenance) | 12 weeks on / 4 off |
| Injury recovery | BPC-157 + TB-500 | GHK-Cu (skin/collagen) | 4–8 weeks |
| Competition prep (cut) | CJC-1295 + Ipamorelin | GHK-Cu | 12 weeks continuous |
| GH axis optimization | CJC-1295 (with DAC) | Ipamorelin | 12 weeks on / 4 off |
| Connective tissue health | BPC-157 | TB-500 (Wolverine Blend) | 4–8 weeks |
The most research-supported peptides for bodybuilding are: IGF-1 LR3 (direct mTOR activation and satellite cell proliferation — the most potent anabolic peptide in research), CJC-1295 + Ipamorelin (GHRH + GHSR agonist combination for sustained GH/IGF-1 elevation and body recomposition), and BPC-157 + TB-500 (injury prevention and recovery stack to maintain training continuity). GHK-Cu is increasingly used for skin quality during bulk/cut cycles.
IGF-1 LR3 binds the IGF-1 receptor (IGF-1R) and activates the PI3K/Akt/mTOR signaling cascade — the primary anabolic pathway for muscle protein synthesis. It also activates satellite cells (muscle stem cells), promoting hyperplasia (new muscle fiber formation) rather than just hypertrophy. Its extended half-life (~20 hours vs 12–15 minutes for native IGF-1) allows once-daily dosing. Typical research protocol: 20–100mcg post-workout for 4–6 week cycles.
CJC-1295 (GHRH analogue) + Ipamorelin (GHSR agonist) is the most widely researched GH-stimulating stack. CJC-1295 extends the amplitude of GH pulses; Ipamorelin selectively triggers GH release without significant cortisol or prolactin elevation. Together they produce synergistic GH pulses 3–5x above baseline. Research protocol: 100–200mcg of each, injected 30–60 minutes before sleep (during the natural GH pulse window). Benefits include improved body composition, fat loss, and overnight recovery.
No — peptides operate through physiological signaling pathways (GH axis, IGF-1 axis, tissue repair) rather than direct androgen receptor activation. Their anabolic effects are more modest than supraphysiological steroid doses but with a substantially different safety profile. Peptides are typically used for: accelerating recovery between sessions, optimizing GH/IGF-1 axis function, injury prevention, and body recomposition — not as a replacement for the direct anabolic effects of androgens.
Yes. IGF-1 LR3, CJC-1295, Ipamorelin, BPC-157, and TB-500 are all prohibited by WADA (S2 category — Peptide Hormones, Growth Factors, Related Substances and Mimetics). WADA-accredited laboratories can detect these compounds in urine and blood. Detection windows vary by compound and dose. Competitive athletes subject to any anti-doping program should not use these compounds.
A research-based bulking protocol typically combines: CJC-1295 (with DAC, 2mg/week) + Ipamorelin (200–300mcg 2–3x/day) for GH/IGF-1 axis optimization, IGF-1 LR3 (50–100mcg post-workout, 4–6 week cycles with equal time off) for direct anabolic signaling, and BPC-157 (250–500mcg/day) for connective tissue protection during heavy training. This stack targets GH release, downstream IGF-1 production, and direct IGF-1R activation simultaneously.
IGF-1 LR3: 4–6 weeks maximum, then equal time off (receptor desensitization occurs with prolonged use). CJC-1295 with DAC: 12 weeks on / 4 weeks off is common; without DAC, continuous use is more feasible due to shorter half-life. BPC-157 and TB-500: 4–8 weeks for injury management, then off cycle. Ipamorelin: can be used continuously or cycled. Most researchers cycle all peptides to maintain receptor sensitivity.
BPC-157 (500mcg/day near injury sites) accelerates tendon, ligament, and muscle repair through VEGF upregulation and FAK-paxillin pathway activation. TB-500 (2–2.5mg 2x/week) provides systemic anti-inflammatory effects and reduces DOMS through actin regulation and MMP-2 upregulation. The Wolverine Blend (BPC-157 + TB-500 pre-combined) is the most convenient format for comprehensive recovery support during high-volume training.
Purgo Labs supplies ≥99% purity peptides with third-party COA verification. Use code HEALTH for 15% off.
Shop Purgo Labs — Use Code HEALTHAffiliate disclosure: CompoundReview earns a commission on purchases made through this link. See our editorial methodology.
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.